Global Atrial Fibrillation Market, by Procedure (Pharmacological (Anti-arrhythmic and Anti-coagulant), Non-Pharmacological (Catheter Ablation Procedures, Maze surgery and Electric Cardioversion), by Technology (Radiofrequency, Laser, Cryotherapy and Others), by End User Hospitals, Speciality, Clinics and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 21,042.7 Million in 2022 and is expected to exhibit a CAGR of 13.4% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
The increasing artificial intelligence to detect atrial fibrillation is expected to drive the market growth over the forecast period. For instance, on June 28, 2022, OSRAM, which offers innovative and sustainable lighting solutions, launched AS705x, which allows the end user to capture biosignals such as heart rate measurement (HRM) and galvanic skin resistance (GSR).
Global Atrial Fibrillation Market– Impact of Coronavirus (COVID-19) Pandemic
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has swept the world over the past year, causing frightening morbidity and mortality. SARS-CoV-2 primarily affects the lungs, where it can cause coughing and dyspnea as well as other pulmonary symptoms that can progress in severe cases to acute respiratory distress syndrome and death. However, it can also affect other organs, especially when there are complex cardiovascular comorbidities present. While the underlying cardiovascular disorders are frequently accompanied with comorbidities, which may lead to raised infection rates and mortality, acute respiratory tract infections are recognized triggers of acute exacerbations of cardiovascular diseases.
Global Atrial Fibrillation Market: Key Developments
In August 2019, a team of researchers from Mayo Clinic reported development of a rapid, Artificial Intelligence (AI) based test that can identify patients with an abnormal heart rhythm, in the journal The Lancet.
In February 2022, Boston Scientific Corporation, which is a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, urology and gynecology, announced acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures. This acquisition will allows Boston Scientific to integrate the Baylis platforms with existing electrophysiology and structural heart offerings, further strengthening the company’s position within the highest growth cardiology markets.
On July, 26, 2022, Xplore Lifestyle, which is a patient monitoring solution provider, partners with CardiacSense, which is a developer of a wearable technology for continuous cardiac arrhythmia detection and vital signs monitoring, launched medical-grade smartwatch. This medical device is capable of differentiating between a Normal Heart Rhythm from an Abnormal/Irregular Heart Rhythm ( Arrhythmia ), especially Atrial Fibrillation (AFib).
Browse 37 Market Data Tables and 33 Figures spread through 162 Pages and in-depth TOC on “Global Atrial Fibrillation Market”- Forecast to 2030, Global Atrial Fibrillation Market, by by Procedure (Pharmacological (Anti-arrhythmic and Anti-coagulant), Non-Pharmacological (Catheter Ablation Procedures, Maze surgery and Electric Cardioversion), by Technology (Radiofrequency, Laser, Cryotherapy and Others), by End User Hospitals, Speciality, Clinics and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/atrial-fibrillation-market-205
Moreover, increase in incidence rate of atrial fibrillation due to increasing prevalence of disorders such as hypertension and obesity are expected to drive market growth during the forecast period. For instance, according to data published in June 2022, on World Health Organization (WHO), stated that by April 2022, in India more than 2.5 million patients with hypertension have been enrolled in over 15 000 health facilities.
Key Takeaways of the Global Atrial Fibrillation Market:
- The global atrial fibrillation market is expected to exhibit a CAGR of 13.4% during the forecast period due to the increasing adoption of strategies such as collaborations and partnerships by the key players for carrying out research activities on recombinant vaccines. For instance, in March 2022, GE Healthcare, which provides digital infrastructure, data analytics & decision support tools helps in diagnosis, treatment and monitoring of patients, announced partnership with AliveCor, which is a medical device and artificial intelligence (AI) company producing ECG hardware and software for consumer mobile devices. The aims of these partnership is to increase convenience for patients and help reduce cardiac-related hospitalizations by improving the quality and integration of patient data.
- Among end user, hospitals segment is estimated to hold a dominant position in the global atrial fibrillation market over the forecast period, owing to the increased prevalence of atrial fibrillation. For instance, according to data published in July 2022, on Centers for Disease Control and Prevention (CDC), stated that, in 2019, atrial fibrillation caused death of approximately 183,321 people in the U.S.
- Among procedure, catheter ablation procedures segment is estimated to account for the largest market share in the global atrial fibrillation market over the forecast period, owing to increasing catheter ablation procedures. For instance, according to data published in January 2020, on The Heart Rhythm Society (HRS), which is a leading resource on cardiac pacing and electrophysiology, stated that an estimated 75,000 catheter ablation procedures performed each year in the U.S.
Major players operating in the global atrial fibrillation market include AtriCure, Inc., Biosense Webster, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, CardioFocus, Inc., Endoscopic Technologies, Inc., Sanofi Aventis, Johnson and Johnson Ltd., and Abbott Laboratories.
